Conference Agenda
Subject to change, please check back before the event for the most current agenda.
Day 1 – Wednesday June 26, 2024
| START OF CONFERENCE | ||
| Welcome & Opening Remarks | 12:30-12:40pm | Brian M. Culley, CEO, Lineage Cell Therapeutics |
| Presenter’s Address – The Christopher & Dana Reeve Foundation | ||
| 12:40-12:50pm | Marco Baptista, Ph.D., Chief Scientific Officer | |
| Patient Focused Drug Development (PFDD) Overview | ||
| 12:50-1:00pm | Patient Focused Drug Development – A New Collaborative Initiative
Brian M. Culley, CEO, Lineage Cell Therapeutics |
|
| 1:00-1:50pm | PFDD – Why, Who, What & How?
Jonathan Stokes, MBA, Senior Director, Patient-Centered Outcomes Research, AbbVie Linda Jones, PT, PhD, Collaborating Investigator, SCOPE Barry Munro, Chief Development Officer, Canadian Spinal Research Organization Steven Kirshblum, MD, Chief Medical Officer, Kessler Foundation |
|
| BREAK | 1:50-2:00pm | |
| Preclinical Spinal Cord Injury Session | ||
| Introduction | 2:00-2:15pm | Jack Allen, CFA, Senior Research Analyst, Biotechnology, R.W. Baird & Co., Inc.
Adrien Cohen, Founding Managing Director of SCI Ventures |
| Inteligex | 2:15-2:35pm | Paul Bradshaw, MBA, PhD, CEO |
| NeuroHagana Ltd. | 2:35-2:55pm | Angela Ruban, PhD, Founder & CEO |
| Novoron Bioscience | 2:55-3:15pm | Tom Gawriluk, PhD, Program Lead, Spinal Cord Injury |
| Sania Therapeutics | 3:15-3:35pm | Andrew J Murray, PhD, CEO & Co-Founder |
| ReWire Medical | 3:35-3:55pm | Robert L. Rennaker II, PhD, Founder |
| Axonis | 3:55-4:15pm | Joanna Stanicka, PhD, CEO |
| Preclinical Company Q&A Session | 4:15-4:30pm | Jack Allen, CFA, Senior Research Analyst, Biotechnology, R.W. Baird & Co., Inc.
Adrien Cohen, Founding Managing Director of SCI Ventures |
| Presentation – Praxis Spinal Cord Institute | ||
| 4:30-4:45pm | Arushi Raina, MBA, Director, Commercialization | |
| Concluding Remarks | ||
Day 2 – Thursday June 27, 2024
| START OF CONFERENCE | ||
| Welcome & Opening Remarks | 8:00-8:10am | Brian M. Culley, CEO, Lineage Cell Therapeutics |
| Presenter’s Address – California Institute for Regenerative Medicine (CIRM) | ||
| 8:10-8:40am | Lila R. Collins, PhD, Associate Director, Portfolio Development and Review | |
| Patient Focused Drug Development (PFDD) – Update from PFDD Community Working Group & Call to Action | ||
| 8:40-9:00am | Marco Baptista, PhD, Chief Scientific Officer, Christopher & Dana Reeve Foundation
Brian M. Culley, CEO, Lineage Cell Therapeutics |
|
| The Persons With Lived Experience Panel – Direct & Caregiver Perspectives | ||
| Panelists | 9:00-10:00am | Jerod Nieder & Hanna Nieder
Michaela Devins & Kyle Devins |
| Moderator | Joseph Pantginis, PhD, Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., LLC | |
| BREAK | 10:00-10:10am | |
| Acute Phase of Spinal Cord Injury – A Surgeon’s Perspective | ||
| 10:10-10:40am | Richard Fessler, MD, PhD, Professor, Department of Neurosurgery, RUSH University Medical Center | |
| Spinal Cord Injury Clinical Trials – Successes, Failures, Demographic Considerations & Obstacles | ||
| 10:40-11:10am | James Guest, MD, PhD, FACS, Clinical Professor, Department of Neurological Surgery, The Miami Project to Cure Paralysis, Professor, University of Miami Miller School of Medicine | |
| Complexity of Clinical Trials During Acute Rehabilitation | ||
| 11:10-11:30am | Steven Kirshblum, MD, Chief Medical Officer, Kessler Foundation | |
| Subliminal Interference With Recovery After Spinal Cord Injury | ||
| 11:30-11:40am | Jeffrey C. Petruska, PhD, Associate Professor, University of Louisville, Department of Anatomical Sciences and Neurobiology, KY Spinal Cord Injury Research Center, Department of Neurological Surgery | |
| Thought Leader Panel and Q&A Session | ||
| Panelists | 11:40am-12:00pm | Richard Fessler, MD, PhD
James Guest, MD, PhD, FACS Steven Kirshblum, MD Jeffrey C. Petruska, PhD |
| Moderator | Joseph Pantginis, PhD, Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., LLC | |
| LUNCH | 12:00 – 1:00pm | |
| Clinical Spinal Cord Injury Session | ||
| ONWARD Medical N.V. | 1:00-1:15pm | Aditi Roy, VP Communications
Candy Tefertiller, PT, DPT, PhD, NCS, Executive Director of Research and Evaluation, Craig Hospital |
| AbbVie Inc. | 1:15-1:30pm | Kimberly Pfleeger, PhD, Sr. Scientific Director, Neuroscience Development |
| Lineage Cell Therapeutics, Inc. | 1:30-1:45pm | Brian Culley, Chief Executive Officer |
| Neuralink | 1:45-2:00pm | Dan Adams, PhD, Neuroengineer |
| NervGen Pharma Corp | 2:00-2:15pm | Michael Kelly, MBA, CEO |
| Kringle Pharma | 2:15-2:30pm | Kiichi Adachi, President and CEO |
| Clinical Company Panel and Q&A Session | 2:30-3:15pm | Moderated by Joseph Pantginis, PhD, Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., LLC |
| BREAK | 3:15-3:30pm | |
| Investors’ Perspectives on Spinal Cord Injury – Understanding and Capitalizing on the Investor’s Mindset | ||
| 3:30-4:30pm | Tari Suprapto, PhD, RTTP, Director, Search & Evaluation, Novo Nordisk
Ilan Zipkin, Ph.D., Venture Partner at Breakout Ventures, CEO of Supercede Therapeutics Moderated by Liz Meeks, Investment Banker, Leerink Partners |
|
| Christopher & Dana Reeve Foundation – Team Reeve 2024 Campaign | ||
| 4:30-4:40pm | David Digby, Director, Neuroscience, Global Commercial Development, AbbVie | |
| Concluding Remarks 4:40 – 4:45pm | ||
| Network Reception on Sanford Consortium Terrace 4:45 – 6:45pm | ||